SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

LivaNova PLC (LIVN) News

Follow LivaNova PLC (LIVN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 22 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol LIVN Asset equity Sector Markets 90 days 18 Last 90.73 Updated Nov 05, 2026, 06:19 PM UTC Open live news feed Open LIVN chart & news
L Form SCHEDULE 13G/A LivaNova PLC Filed by: FMR LLC Filed on: November 5, 20 EQUITY | Nov 05, 2026, 06:19 PM UTC M LivaNova Reports Third-Quarter Revenue of $393.15 Million LivaNova reported third-quarter 2026 revenue of $393.15 million, up 9.9% year over year. Net income rose 28% to $34.29 million, while diluted EPS was $0.11 versus $0.49 a year earlier. EQUITY | Nov 04, 2026, 08:11 PM UTC M LivaNova Reports Q3 Revenue of $393.1 Million, Raises 2026 Guidance LivaNova reported Q3 revenue of $393.1 million, up 9.9% year over year on a reported basis and 10.0% on a constant-currency basis, with adjusted diluted EPS of $1.23. It raised 2026 revenue-growth guidance to 9%–10% and EQUITY | Nov 04, 2026, 02:03 PM UTC M LivaNova Raises Full-Year Earnings and Revenue-Growth Projections The medical-technology maker lifted its adjusted earnings and revenue-growth projections for the year. Its shares rose 12% to $89.94 premarket Wednesday. EQUITY | Nov 04, 2026, 01:28 PM UTC M LivaNova Raises 2026 Revenue Growth Forecast to 9%-10% LivaNova raised its 2026 constant-currency revenue growth forecast to 9%-10%. EARNINGS | Nov 04, 2026, 11:42 AM UTC M LivaNova raises 2026 currency-adjusted revenue growth outlook EARNINGS | Nov 04, 2026, 11:42 AM UTC M LivaNova Expects 2026 Adjusted EPS of $4.40–$4.50 LivaNova expects 2026 adjusted EPS of $4.40 to $4.50, versus a FactSet estimate of $4.36. EARNINGS | Nov 04, 2026, 11:27 AM UTC M LivaNova Reports Q3 Results, Raises 2026 Revenue and EPS Guidance LivaNova reported 9.9% revenue growth, or 10.0% on a constant-currency basis, and raised its full-year 2026 revenue and adjusted diluted EPS guidance. EQUITY | Nov 04, 2026, 11:11 AM UTC M LivaNova Q3 Revenue Beats Estimates on Cardiopulmonary Strength EQUITY | Nov 04, 2026, 11:11 AM UTC M LivaNova Q3 GAAP Diluted EPS Falls 78% to $0.11 EARNINGS | Nov 04, 2026, 11:08 AM UTC M LivaNova Q3 revenue reaches $393.1 million LivaNova reported Q3 revenue of $393.1 million versus the IBES estimate of $381.1 million. EQUITY | Nov 04, 2026, 11:03 AM UTC L LivaNova Reports Q3 EPS of USD 0.11 EARNINGS | Nov 04, 2026, 11:02 AM UTC M LivaNova reports third-quarter earnings EQUITY | Nov 04, 2026, 11:02 AM UTC M LivaNova Q3 Adjusted EPS $1.23 vs. IBES Estimate $1.06 EARNINGS | Nov 04, 2026, 11:01 AM UTC L LivaNova to Announce Third-Quarter 2026 Results LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern Standar NEWS | Sep 23, 2026, 01:01 PM UTC L LIVN: Growth momentum continues with innovation, reimbursement, and product upgrades fueling future gains Sustained growth is driven by talent, execution, and innovation, with strong tailwinds from reimbursement and clinical data in epilepsy and supply chain improvements. Margin expansion will be reinvested in new growth are NEWS | Sep 15, 2026, 04:53 PM UTC L LIVN: Growth is fueled by innovation, new product launches, and strong clinical and reimbursement tailwinds Sustained double-digit growth is driven by talent, execution, and innovation, with new market entries and product launches in epilepsy and cardiopulmonary segments. Margin expansion will fund OSA investments, and strong NEWS | Sep 15, 2026, 04:27 PM UTC L Piper Sandler raises LivaNova price target to $90 from $87 Piper Sandler raised its LivaNova price target to $90.00 per share from $87.00, according to a Benzinga ratings-action item. EQUITY | Sep 02, 2026, 04:42 PM UTC L LivaNova Raises FY2026 Adj EPS Guidance from $4.20-$4.30 to $4.30-$4.40 vs $4.25 Est; Raises FY2026 Sales Guidance from $1.445B-$1.458B to $ LivaNova (NASDAQ: LIVN ) raises FY2026 Adj EPS guidance from $4.20-$4.30 to $4.30-$4.40 vs $4.25 analyst estimate. Raises FY2026 sales outlook from $1.445 billion-$1.458 billion to $1.499 billion-$1.513 billion vs $1.507 EARNINGS | Aug 05, 2026, 10:01 AM UTC L This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst Dav EQUITY | Jul 01, 2026, 11:02 AM UTC L Freedom Capital Markets Initiates Coverage On LivaNova with Hold Rating, Announces Price Target of $81 Freedom Capital Markets analyst Keith Hinton initiates coverage on LivaNova (NASDAQ: LIVN ) with a Hold rating and announces Price Target of $81. EQUITY | Jul 01, 2026, 08:43 AM UTC M LIVN: Keybanc Raises Target Keybanc maintains overweight rating on LivaNova and raises price target to $92 EQUITY | Jun 22, 2026, 01:15 PM UTC